Evidence map›Paper›PMID 25416320›Full record

ReviewDrug safety2015

The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

Hazel Mae A Abraham, C Michael White, William B White

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug safety, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 5 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 5 syntheses or guidelines pooled it, 170 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Hazel Mae A AbrahamDivision of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut Health Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06032, USA.
C Michael White
William B White
University of Connecticut · USHartford Hospital · US

Funding

Intensive Blood Pressure Reduction to Lessen Functional DeclineR01AG022092 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI WHITE, WILLIAM BARRY, WOLFSON, LESLIE · 2004 to 2017
$6.6M
Contingency Management for Initiating Smoking AbstinenceR01DA024667 · NIDA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI WHITE, WILLIAM BARRY · 2008 to 2012
$2.8M
NIA NIH HHS R01 AG022092NIDA NIH HHS R01 DA024667
6 · The paper itself

Abstract

All national guidelines for the management of hypertension recommend angiotensin receptor blockers (ARBs) as an initial or add-on antihypertensive therapy. The eight available ARBs have variable clinical efficacy when used for control of hypertension. Additive blood pressure-lowering effects have been demonstrated when ARBs are combined with thiazide diuretics or dihydropyridine calcium channel blockers, augmenting hypertension control. Furthermore, therapeutic use of ARBs goes beyond their antihypertensive effects, with evidence-based benefits in heart failure and diabetic renal disease particularly among angiotensin-converting enzyme inhibitor-intolerant patients. On the other hand, combining renin-angiotensin system blocking agents, a formerly common practice among medical subspecialists focusing on the management of hypertension, has ceased, as there is not only no evidence of cardiovascular benefit but also modest evidence of harm, particularly with regard to renal dysfunction. ARBs are very well tolerated as monotherapy, as well as in combination with other antihypertensive medications, which improve adherence to therapy and have become a mainstay in the treatment of stage 1 and stage 2 hypertension.

Indexed as

Angiotensin Receptor AntagonistsAnimalsAntihypertensive AgentsBlood PressureCardiovascular DiseasesDrug Therapy, CombinationHumansHypertensionMedication AdherencePractice Guidelines as TopicAngiotensin Receptor AntagonistsAntihypertensive Agents

Identifiers

PMID25416320
PMCPMC4303500
OpenAlexW2006584351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.